Literature DB >> 15728491

EBV-induced gene 3 transcription is induced by TLR signaling in primary dendritic cells via NF-kappa B activation.

Stefan Wirtz1, Christoph Becker, Massimo C Fantini, Edward E Nieuwenhuis, Ingrid Tubbe, Peter R Galle, Hans-Jörg Schild, Mark Birkenbach, Richard S Blumberg, Markus F Neurath.   

Abstract

The EBV-induced gene 3 (EBI3) is expressed in dendritic cells (DCs) and part of the cytokine IL-27 that controls Th cell development. However, its regulated expression in DCs is poorly understood. In the present study we demonstrate that EBI3 is expressed in splenic CD8(-), CD8(+), and plasmacytoid DC subsets and is induced upon TLR signaling. Cloning and functional analysis of the EBI3 promoter using in vivo footprinting and mutagenesis showed that stimulation via TLR2, TLR4, and TLR9 transactivated the promoter in primary DCs via NF-kappaB and Ets binding sites at -90 and -73 bp upstream of the transcriptional start site, respectively. Furthermore, we observed that NF-kappaB p50/p65 and PU.1 were sufficient to transactivate the EBI3 promoter in EBI3-deficient 293 cells. Finally, induced EBI3 gene expression in DCs was reduced or abrogated in TLR-2/TLR4, TLR9, and MyD88 knockout mice, whereas both basal and inducible EBI3 mRNA levels in DCs were strongly suppressed in NF-kappaB p50-deficient mice. In summary, these data suggest that EBI3 expression in DCs is transcriptionally regulated by TLR signaling via MyD88 and NF-kappaB. Thus, EBI3 gene transcription in DCs is induced rapidly by TLR signaling during innate immune responses preceding cytokine driven Th cell development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15728491     DOI: 10.4049/jimmunol.174.5.2814

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  EBI3 regulates the NK cell response to mouse cytomegalovirus infection.

Authors:  Helle Jensen; Shih-Yu Chen; Lasse Folkersen; Garry P Nolan; Lewis L Lanier
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-31       Impact factor: 11.205

2.  IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis.

Authors:  Nasim Akhtar Ansari; Rajiv Kumar; Shalini Gautam; Susanne Nylén; Om Prakash Singh; Shyam Sundar; David Sacks
Journal:  J Immunol       Date:  2011-02-28       Impact factor: 5.422

3.  Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis.

Authors:  Stefan Wirtz; Ulrike Billmeier; Tamuna Mchedlidze; Richard S Blumberg; Markus F Neurath
Journal:  Gastroenterology       Date:  2011-08-04       Impact factor: 22.682

Review 4.  IL-35 and Autoimmunity: a Comprehensive Perspective.

Authors:  Jinjung Choi; Patrick S C Leung; Christopher Bowlus; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

5.  Interleukin-27 (IL-27) Mediates Susceptibility to Visceral Leishmaniasis by Suppressing the IL-17-Neutrophil Response.

Authors:  Gustavo F S Quirino; Manuela S L Nascimento; Marcela Davoli-Ferreira; Lais A Sacramento; Mikhael H F Lima; Roque P Almeida; Vanessa Carregaro; João Santana Silva
Journal:  Infect Immun       Date:  2016-07-21       Impact factor: 3.441

6.  Memory CD4 T cells induce selective expression of IL-27 in CD8+ dendritic cells and regulate homeostatic naive T cell proliferation.

Authors:  Jeong-Su Do; Anabelle Visperas; Keunhee Oh; Stephen A Stohlman; Booki Min
Journal:  J Immunol       Date:  2011-11-23       Impact factor: 5.422

Review 7.  Interleukin 12 a key immunoregulatory cytokine in infection applications.

Authors:  Therwa Hamza; John B Barnett; Bingyun Li
Journal:  Int J Mol Sci       Date:  2010-02-26       Impact factor: 5.923

8.  Production of interleukin-27 by human neutrophils regulates their function during bacterial infection.

Authors:  Darawan Rinchai; Prasong Khaenam; Chidchamai Kewcharoenwong; Surachat Buddhisa; Rungnapa Pankla; Damien Chaussabel; Gregory J Bancroft; Ganjana Lertmemongkolchai
Journal:  Eur J Immunol       Date:  2012-10-25       Impact factor: 5.532

9.  Differential effect of IL-27 on developing versus committed Th17 cells.

Authors:  Mohamed El-behi; Bogoljub Ciric; Shuo Yu; Guang-Xian Zhang; Denise C Fitzgerald; Abdolmohamad Rostami
Journal:  J Immunol       Date:  2009-09-28       Impact factor: 5.422

Review 10.  Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection.

Authors:  Sanjay Swaminathan; Lue Dai; H Clifford Lane; Tomozumi Imamichi
Journal:  Cytokine Growth Factor Rev       Date:  2013-08-17       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.